Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

NCT07563881 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

333

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Seizure
Epilepsy
Focal Epilepsy

Interventions

DRUG: RAP-219
DRUG: RAP-219
OTHER: Placebo

Sponsor

Rapport Therapeutics Inc.